Примери за използване на Do not outweigh на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
In other longer lasting conditions, the benefits of this medicine do not outweigh the risks of side effects.
The researchers say that if the positives do not outweigh the negatives by five to one, a couple will more than likely be heading for the divorce courts.
In such cases, it is important to introduce antibiotics,the side effects of which do not outweigh the benefits.
For most people,these negative side effects do not outweigh the potential for strength- no matter how fast it can occur.
The FDA's recommendation is based on four studies showing the drug's benefits do not outweigh its risks.
The Agency therefore concluded that the benefits of Paclitaxel Hetero do not outweigh its risks and recommended that the marketing authorisation should not be granted in the concerned Member States.
Stacking this steroid is recommended,as the benefits of using this steroid alone do not outweigh any negatives.
Therefore the CHMP concluded that the benefits of Levothyroxine Alapis do not outweigh its risks, and that the marketing authorisation should not be granted in the concerned Member States.
Moms and dads and doctors must closely monitor a youngster's progress and reactions while he orshe is taking a medication to be sure that any negative side effects of the treatment do not outweigh the benefits.
Therefore, if you find such a serious disagreement,is to assess whether they do not outweigh the value of friendship and whether it is possible at all under these conditions.
Parents and health care professionals must closely monitor a child's progress and reactions while he orshe is taking a medication to be sure that any negative side effects of the treatment do not outweigh the benefits.
The German agency concluded that the benefits of bufexamac-containing medicines do not outweigh their risks, and recommended that the marketing authorisations be withdrawn in Germany.
Based on the evaluation of the currently available data andthe scientific discussion within the Committee, the CVMP concluded that the benefits of veterinary medicines containing paromomycin given to pigs by injection into the muscle do not outweigh their risks.
Apparently, the business sector feels comfortable in the dollar system, andthe risks of secondary sanctions do not outweigh the benefits the system presents and the costs of its transformation.
The CHMP concluded that the benefits of these medicines do not outweigh their risks and therefore recommended that the marketing authorisations for clobutinol-containing medicines be withdrawn throughout the EU(Article 107(2) procedure).
The new data provided does not change the conclusions from the previous 2013 referral that the benefits of HES solutions for infusion do not outweigh the serious risks in patients with sepsis or critical illness.
Nevertheless, all the weaknesses in Dostoevsky's work do not outweigh the merits, and so the author remains beloved by millions of readers, even if they don't share all his beliefs.
Therefore, in the light of current standard of care available, the Committee concluded that the benefits of Caustinerf arsenical andYranicid arsenical do not outweigh their risks and recommended that their marketing authorisations be revoked.
The CHMP therefore concluded that the benefits of Canazole do not outweigh its risks and recommended that the marketing authorisation should not be granted in the concerned Member State.
Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of all medicines containing dextropropoxyphene,either on its own or in combination, do not outweigh their risks.
The EMA has concluded that the benefits of Caustinerf arsenical, Yranicid arsenical andassociated names do not outweigh their risks and has recommended that their marketing authorisations in the EU be revoked.
Your interests, fundamental rights and freedoms do not outweigh our interest in advertising, as we provide you with comprehensive information about data collection within the framework of our Privacy Policy and you have the option of opting out(via link or browser settings) at any time.
The Agency's Committee for Medicinal Products for Veterinary Use(CVMP)concluded that the benefits of these medicines do not outweigh their risks because of inadequate data supporting their use in pigs and the possibility of bacterial resistance.
The Agency concluded that the benefits of Paclitaxel Hetero do not outweigh its risks, and the marketing authorisation cannot be granted in Portugal or in other Member States of the EU(Germany, the Netherlands and the UK).
Therefore, on the basis of the evaluation of these data and the scientific discussion within the Committee,the CHMP concluded that the benefits of benfluorex-containing medicines do not outweigh their risks, and therefore recommended that the marketing authorisation of these medicines be revoked.
Their interests, fundamental rights andfundamental freedoms do not outweigh our interest in advertising, since we inform you comprehensively about the data collection in the context of our privacy policy and you always have the option of opting out(via link or browser settings).
Based on the evaluation of the currently available data and the scientific discussion within the Committee,the CHMP concluded that the benefits of bufexamac-containing medicines do not outweigh their risks, and therefore recommended that all marketing authorisations be revoked in the EU.
Your interests, fundamental rights andfundamental freedoms do not outweigh our interest in advertising, since we inform you comprehensively about the data collection within the scope of our data protection declaration and you have the possibility of an opt-out(via link or browser settings) at any time.
Based on evaluation of the currently available data and the scientific discussion within the Committee,the CHMP concluded that the benefits of Myderison do not outweigh its risks, and therefore the marketing authorisation should not be granted in the concerned Member States.
The CMDh agreed with the PRAC conclusion that the benefits of these medicines do not outweigh their risks, and adopted a final position that the marketing authorisations should be withdrawn throughout the EU.